WTWan-Chuan Tsai

Wan-Chuan Tsai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wan-Chuan Tsai has a total of 48 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nonclassical Monocyte Expansion Is Independently Associated with Anemia Severity in Patients with ESKD

    by Wei-Yen Chen, Bing-Hung Huang, Feng-Jung Yang, Kai-Hsiang Shu, Wan-Chuan Tsai, Yu-Sen Peng, Shih-Ping Hsu, Yi-Fang Chuang, Yen-Ling Chiu

    Key Points: Nonclassical monocyte expansion is independently associated with lower hemoglobin in patients on hemodialysis after multivariable adjustment. This monocyte–anemia association is independent of systemic inflammation but linked to altered iron homeostasis markers. The association is the strongest in diabetic patients, suggesting that monocyte profiling may identify nontraditional anemia risk. Background: Anemia remains a major contributor to morbidity and mortality in patients treated by hemodialysis despite current anemia management strategies. Nonclassical monocytes (CD14 + CD16 ++ ), which expand in ESKD and participate in iron recycling through heme scavenging, represent an unexplored link to anemia in this population. Methods: In this two-center, cross-sectional analysis of 408 patients treated by prevalent hemodialysis from the prospective Immunity in End-Stage Renal Disease (iESRD) cohort, monocyte subsets were quantified by multicolor flow cytometry. Associations between nonclassical monocyte percentage (%M3) and hemoglobin were evaluated using Spearman rank correlations and multivariable linear regression adjusted for demographics, dialysis vintage, erythropoietin dose, iron parameters, inflammatory markers, and comorbidities. Results: The mean age was 62±12 years, 57% were male, and 45% had diabetes. Patients in the highest %M3 tertile had lower hemoglobin than those in the lowest tertile (10.6±1.2 versus 11.1±1.6 g/dl; P = 0.01). In multivariable regression, each one-tertile higher %M3 was independently associated with 0.29 g/dl lower hemoglobin ( β =−0.29; 95% confidence interval, −0.43 to −0.15; P < 0.001), and this association persisted after further adjustment for BUN and serum creatinine ( β =−0.31; P < 0.001). The association was not attenuated by adjustment for high-sensitivity C-reactive protein, and %M3 showed no correlation with IL-6 or TNF- α . The association was the strongest among diabetic patients (ρ=−0.27; P < 0.001). Conclusions: Nonclassical monocyte expansion is independently associated with anemia severity in patients treated by hemodialysis through an inflammation-independent pathway involving altered iron homeostasis. Monocyte subset profiling may identify patients at risk of refractory anemia.

  • National Prevalence, Regional Distribution, and Risk Factors for CKD in Taiwan

    by Min-De Ang, Chia-Yun Cheng, Wan-Chuan Tsai, Ping-Hsiu Tsai, Le-Yin Hsu, Mei-Ju Ko, Kuo-Liong Chien, Kuan-Yu Hung, Hon-Yen Wu

    Taiwan has exhibited one of the highest incidence and prevalence rates of dialysis globally, yet updated national data on CKD has been lacking for nearly two decades. We estimated the national CKD prevalence, identified associated risk factors, and evaluated CKD of undetermined etiology (CKDu) in Taiwan. In this cross-sectional study, we analyzed data from 4298 adults age 20 years or older who participated in the 2017–2020 Nutrition and Health Survey in Taiwan, a nationally representative survey employing stratified, three-stage, clustered sampling across 20 administrative divisions. CKD was defined as an eGFR 2 or an urine albumin-to-creatinine ratio ≥30 mg/g. Data on demographics, comorbidities, lifestyle factors, and socioeconomic status were collected to identify risk factors associated with CKD. The primary outcome was the national prevalence of CKD. Secondary outcomes included regional CKD prevalence, major risk factors associated with CKD, and characteristics of CKDu. The national CKD prevalence was 10.0%, affecting 1.91 million adults. Prevalence rates for CKD stages 1, 2, 3a, 3b, 4, and 5 were 0.7%, 2.1%, 4.6%, 1.9%, 0.6%, and 0.05%, respectively. CKD prevalence was higher in men (11.9%) than in women (8.1%) and varied regionally, with the highest rate in eastern Taiwan (13.9%), followed by the central (11.5%), southern (11.1%), and northern (8.0%) regions. CKD was independently associated with male sex, older age, diabetes, hypertension, hypertriglyceridemia, gout/hyperuricemia, lower socioeconomic status, and physical inactivity. Only 8% of the patients with CKD were aware of their kidney condition, and CKDu accounted for approximately one-eighth of the CKD population. In conclusion, CKD affects approximately 10% of Taiwanese adults, with marked geographic disparities and low awareness. These findings underscore the need for targeted interventions addressing modifiable risk factors and enhanced screening to improve CKD detection and prevention.


  • Open Access

    Longitudinal dynamics of humoral immune responses following serial COVID-19 vaccinations and breakthrough infections in dialysis patients

    by Wan-Chuan Tsai, Fang-Yeh Chu, Yen-Ling Chiu, Hon-Yen Wu, Ju-Yeh Yang, Mei-Fen Pai, Shih-Ping Hsu, Kuei-Tung Tung, Kai-Hsiang Shu, Wan-Yu Lin, et al.

    Patients with end-stage kidney disease (ESKD) undergoing dialysis have impaired vaccine responses. Many countries recommend extended primary series and regular COVID-19 boosters for this group, but data on long-term humoral responses after repeated doses or breakthrough infection are limited. In this prospective cohort study of 498 dialysis patients, most received homologous ChAdOx1 nCoV-19 as a primary series, mRNA-1273 for the third and fourth doses, and bivalent Moderna vaccines for later doses. Neutralizing antibodies (via surrogate virus neutralization test) and anti - receptor-binding domain (RBD) antibodies were measured up to 15 months post-vaccination or infection. The primary endpoint was seroprotection (neutralization inhibition ≥30%); the secondary was anti-RBD seroprotection (≥100 U/mL). Seroprotection increased from 16% (neutralizing) and 2% (anti-RBD) after the first dose to ~100% after the third and subsequent doses. Neutralizing inhibition rose from 5% (dose 1) to ~90% (doses 4-6). Anti-RBD titers declined 66%-85% by 6 months and >90% by 12-15 months. Younger age, receipt of a fourth dose, and vaccine platform were significant predictors of neutralizing titers. Breakthrough infection led to higher and more sustained anti-RBD titers, particularly in patients with hybrid immunity. Patients with stronger immunity had fewer symptoms. In conclusion, serial COVID-19 vaccinations elicited robust humoral responses in dialysis patients, with younger age, receipt of a booster dose, and vaccine platform, emerging as significant predictors. Although antibody titers declined over time, they were better maintained in those with hybrid immunity. These findings support the implementation of personalized booster strategies to optimize protection in immunocompromised populations.

  • Open Access

    Role of Staphylococcus aureus Nasal Carriage in Uremic Pruritus and Infection in Hemodialysis Patients

    by Mei‐Ju Ko, Jenny Chiang, Chun‐Hsing Liao, Wan‐Chuan Tsai, Ping‐Hsiu Tsai, Le‐Yin Hsu, Fang‐Yeh Chu, Yen‐Ling Chiu, Hon‐Yen Wu

    Background: While Staphylococcus aureus ( S. aureus ) is a well‐recognized concern in hemodialysis (HD) patients, its role in uremic pruritus remains unknown. This study investigated the impact of S. aureus nasal carriage on the prevalence and severity of uremic pruritus and its association with subsequent infection in HD patients. Methods: We conducted a prospective cohort study from April 2019 to January 2020, enrolling 100 HD patients in Taiwan. Nasal swab cultures determined S. aureus colonization status. Odds ratios (ORs) for uremic pruritus, effect estimates for pruritus intensity, and hazard ratios (HRs) for subsequent S. aureus infections were assessed. Results: S. aureus nasal carriage was detected in 24% of HD patients and was more prevalent among those with uremic pruritus (32.7% vs. 13.3%, p = 0.02). S. aureus nasal carriage was associated with a significantly increased risk of uremic pruritus (OR: 4.21; 95% confidence interval [CI], 1.34–13.24, p < 0.01) and correlated with higher pruritus intensity (effect estimate: 1.18; 95% CI, 0.05–2.30; p = 0.04). During a median follow‐up of 8.97 months, five patients developed S. aureus infections. While S. aureus nasal carriage showed a trend toward an increased risk of subsequent infection, the finding did not reach statistical significance (HR: 50.93; 95% CI, 0.62–4181.02; p = 0.08). Conclusions: S. aureus nasal carriage is significantly associated with the prevalence and severity of uremic pruritus in HD patients. Larger studies are needed to confirm its role in infection risk and to explore decolonization as a potential therapeutic strategy.


  • The risk of genito-urinary infections with sodium-glucose cotransporter-2 inhibitors: duration rather than dose matter?

    by Wan-Chuan Tsai, Yu-Sen Peng, Hon-Yen Wu

    We read with great interest the well-conducted article by Sridharan et al. [1], which enrolled 264 articles for the evaluation of risk of urinary tract infection (UTI) and genital infection (GI) wi...

  • Open Access

    Physician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study

    by Ju-Yeh Yang, Kai-Hsiang Shu, Yu-Sen Peng, Shih-Ping Hsu, Yen-Ling Chiu, Mei-Fen Pai, Hon-Yen Wu, Wan-Chuan Tsai, Kuei-Ting Tung, Raymond N Kuo

    Background: Previous studies on clinical decision support systems (CDSSs) for the management of renal anemia in patients with end-stage kidney disease undergoing hemodialysis have previously focused solely on the effects of the CDSS. However, the role of physician compliance in the efficacy of the CDSS remains ill-defined. Objective: We aimed to investigate whether physician compliance was an intermediate variable between the CDSS and the management outcomes of renal anemia. Methods: We extracted the electronic health records of patients with end-stage kidney disease on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center (FEMHHC) from 2016 to 2020. FEMHHC implemented a rule-based CDSS for the management of renal anemia in 2019. We compared the clinical outcomes of renal anemia between the pre- and post-CDSS periods using random intercept models. Hemoglobin levels of 10 to 12 g/dL were defined as the on-target range. Physician compliance was defined as the concordance of adjustments of the erythropoietin-stimulating agent (ESA) between the CDSS recommendations and the actual physician prescriptions. Results: We included 717 eligible patients on hemodialysis (mean age 62.9, SD 11.6 years; male n=430, 59.9%) with a total of 36,091 hemoglobin measurements (average hemoglobin and on-target rate were 11.1, SD 1.4, g/dL and 59.9%, respectively). The on-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre: 21.5%; post: 29%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2% (pre-CDSS) to 14.8% (post-CDSS). The average weekly ESA use of 5848 (SD 4211) units per week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6%. In the adjusted random intercept model, the post-CDSS phase showed increased hemoglobin by 0.17 (95% CI 0.14-0.21) g/dL, weekly ESA by 264 (95% CI 158-371) units per week, and 3.4-fold (95% CI 3.1-3.6) increased concordance rate. However, the on-target rate (29%; odds ratio 0.71, 95% CI 0.66-0.75) and failure rate (16%; odds ratio 0.84, 95% CI 0.76-0.92) were reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended toward attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73 g/dL, respectively). Increased ESA and decreased failure rate were completely mediated by physician compliance (from 264 to 50 units and 0.84 to 0.97, respectively). Conclusions: Our results confirmed that physician compliance was a complete intermediate factor accounting for the efficacy of the CDSS. The CDSS reduced failure rates of anemia management through physician compliance. Our study highlights the importance of optimizing physician compliance in the design and implementation of CDSSs to improve patient outcomes.


  • Short-Term Effects of a Therapeutic Diet on Biochemical Parameters in Hemodialysis Patients: A Randomized Crossover Trial

    by Wan-Chuan Tsai, Shih-Ping Hsu, Yen-Ling Chiu, Hon-Yen Wu, Chia-Chin Luan, Ju-Yeh Yang, Mei-Fen Pai, Cheng-Jui Lin, Wan-Yu Lin, Wen-Huei Sun, et al.


  • Extremely Low Dose of Erythropoiesis-Stimulating Agent May Be Associated with Increased Mortality in Hemodialysis Patients

    by Cheng-Wen Yang, Mei-Chen Lin, Kai-Hsiang Shu, Kuei-Tung Tung, Wan-Chuan Tsai, Ju-Yeh Yang, Mei-Fen Pai, Hon-Yen Wu, Yen-Ling Chiu, Yu-Sen Peng, et al.

    Introduction: Although high-dose erythropoiesis-stimulating agent (ESA) has been shown to increase mortality risk and adverse cardiovascular events in hemodialysis patients, the safety of extremely low-dose ESA is unclear. Methods: We retrospectively analyzed the association between ESA dose and mortality in the monthly dosing range of 0–43,000 U of equivalent epoetin alfa in 304 Taiwan hemodialysis patients by using Cox proportional hazard model and cubic spline model. Results: Compared with mean monthly ESA dose of 15,000–25,000 U (mean ± standard deviation 20,609 ± 2,662 U), monthly ESA dose of less than 15,000 U (mean ± standard deviation 7,413 ± 4,510 U) is associated with increased mortality. Monthly ESA dose of 25,001–43,000 U (mean ± standard deviation 31,160 ± 4,304 U) is not associated with higher mortality risk than monthly ESA dose of 15,000–25,000 U. The results were consistent in Cox proportional hazard models and cubic spline models. Subgroup analyses showed no significant heterogeneities among prespecified subgroups. Conclusions: Extremely low dose of ESA in hemodialysis patients may be associated with increased mortality risk. Future studies are warranted to prove this association.

  • Open Access

    Physician Compliance With a Computerized Clinical Decision Support System for Anemia Management of Patients With End-stage Kidney Disease on Hemodialysis: Retrospective Electronic Health Record Observational Study (Preprint)

    by Ju-Yeh Yang, Kai-Hsiang Shu, Yu-Sen Peng, Shih-Ping Hsu, Yen-Ling Chiu, Mei-Fen Pai, Hon-Yen Wu, Wan-Chuan Tsai, Kuei-Ting Tung, Raymond N Kuo

    BACKGROUND Previous studies on clinical decision support systems (CDSSs) for the management of renal anemia in patients with end-stage kidney disease undergoing hemodialysis have previously focused solely on the effects of the CDSS. However, the role of physician compliance in the efficacy of the CDSS remains ill-defined. OBJECTIVE We aimed to investigate whether physician compliance was an intermediate variable between the CDSS and the management outcomes of renal anemia. METHODS We extracted the electronic health records of patients with end-stage kidney disease on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center (FEMHHC) from 2016 to 2020. FEMHHC implemented a rule-based CDSS for the management of renal anemia in 2019. We compared the clinical outcomes of renal anemia between the pre- and post-CDSS periods using random intercept models. Hemoglobin levels of 10 to 12 g/dL were defined as the on-target range. Physician compliance was defined as the concordance of adjustments of the erythropoietin-stimulating agent (ESA) between the CDSS recommendations and the actual physician prescriptions. RESULTS We included 717 eligible patients on hemodialysis (mean age 62.9, SD 11.6 years; male n=430, 59.9%) with a total of 36,091 hemoglobin measurements (average hemoglobin and on-target rate were 11.1, SD 1.4, g/dL and 59.9%, respectively). The on-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre: 21.5%; post: 29%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2% (pre-CDSS) to 14.8% (post-CDSS). The average weekly ESA use of 5848 (SD 4211) units per week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6%. In the adjusted random intercept model, the post-CDSS phase showed increased hemoglobin by 0.17 (95% CI 0.14-0.21) g/dL, weekly ESA by 264 (95% CI 158-371) units per week, and 3.4-fold (95% CI 3.1-3.6) increased concordance rate. However, the on-target rate (29%; odds ratio 0.71, 95% CI 0.66-0.75) and failure rate (16%; odds ratio 0.84, 95% CI 0.76-0.92) were reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended toward attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73 g/dL, respectively). Increased ESA and decreased failure rate were completely mediated by physician compliance (from 264 to 50 units and 0.84 to 0.97, respectively). CONCLUSIONS Our results confirmed that physician compliance was a complete intermediate factor accounting for the efficacy of the CDSS. The CDSS reduced failure rates of anemia management through physician compliance. Our study highlights the importance of optimizing physician compliance in the design and implementation of CDSSs to improve patient outcomes.